These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35594457)

  • 1. The Eczema Area and Severity Index-A Practical Guide.
    Hanifin JM; Baghoomian W; Grinich E; Leshem YA; Jacobson M; Simpson EL
    Dermatitis; 2022 May-Jun 01; 33(3):187-192. PubMed ID: 35594457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group.
    Hanifin JM; Thurston M; Omoto M; Cherill R; Tofte SJ; Graeber M
    Exp Dermatol; 2001 Feb; 10(1):11-8. PubMed ID: 11168575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study.
    Leshem YA; Hajar T; Hanifin JM; Simpson EL
    Br J Dermatol; 2015; 172(5):1353-7. PubMed ID: 25580670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.
    Schmitt J; Langan S; Deckert S; Svensson A; von Kobyletzki L; Thomas K; Spuls P;
    J Allergy Clin Immunol; 2013 Dec; 132(6):1337-47. PubMed ID: 24035157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an Eczema Area and Severity Index Atlas for Diverse Skin Types.
    Silverberg JI; Horeczko J; Alexis A
    Dermatitis; 2024; 35(2):173-177. PubMed ID: 37279030
    [No Abstract]   [Full Text] [Related]  

  • 6. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.
    Chopra R; Vakharia PP; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
    Br J Dermatol; 2017 Nov; 177(5):1316-1321. PubMed ID: 28485036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of remote atopic dermatitis severity assessment with the Eczema Area and Severity Ondex in children using caregiver-provided photos and videos.
    Croce EA; Rathouz PJ; Lopes FCPS; Leszczynska M; Diaz LZ; Levy ML; Ruth JS; Varshney P; Rew L; Matsui EC
    Pediatr Dermatol; 2022 Jul; 39(4):547-552. PubMed ID: 35522088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.
    Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
    Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review.
    Gerbens LA; Prinsen CA; Chalmers JR; Drucker AM; von Kobyletzki LB; Limpens J; Nankervis H; Svensson Å; Terwee CB; Zhang J; Apfelbacher CJ; Spuls PI;
    Allergy; 2017 Jan; 72(1):146-163. PubMed ID: 27322918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial.
    Thomas KS; Bradshaw LE; Sach TH; Cowdell F; Batchelor JM; Lawton S; Harrison EF; Haines RH; Ahmed A; Dean T; Burrows NP; Pollock I; Buckley HK; Williams HC; Llewellyn J; Crang C; Grundy JD; Guiness J; Gribbin A; Wake EV; Mitchell EJ; Brown SJ; Montgomery AA
    Health Technol Assess; 2017 Apr; 21(16):1-260. PubMed ID: 28409557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study.
    Housman TS; Patel MJ; Camacho F; Feldman SR; Fleischer AB; Balkrishnan R
    Br J Dermatol; 2002 Dec; 147(6):1192-8. PubMed ID: 12452870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of quality of life illness in adult patients with atopic dermatitis].
    Villela-Segura U; León-Dorantes G; Mercado-Lara A; Guevara-Sanginés E
    Rev Med Inst Mex Seguro Soc; 2021 Aug; 59(4):306-312. PubMed ID: 35023698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
    Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
    Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.
    Schmitt J; Spuls PI; Thomas KS; Simpson E; Furue M; Deckert S; Dohil M; Apfelbacher C; Singh JA; Chalmers J; Williams HC;
    J Allergy Clin Immunol; 2014 Oct; 134(4):800-7. PubMed ID: 25282560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.
    Iannone M; Tonini G; Janowska A; Dini V; Romanelli M
    Curr Med Res Opin; 2021 Aug; 37(8):1295-1301. PubMed ID: 34027753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
    Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
    Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme.
    Barbier N; Paul C; Luger T; Allen R; De Prost Y; Papp K; Eichenfield LF; Cherill R; Hanifin J
    Br J Dermatol; 2004 Jan; 150(1):96-102. PubMed ID: 14746622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity.
    van Velsen SG; Knol MJ; Haeck IM; Bruijnzeel-Koomen CA; Pasmans SG
    Pediatr Dermatol; 2010; 27(5):470-5. PubMed ID: 20796235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis.
    Gooderham MJ; Bissonnette R; Grewal P; Lansang P; Papp KA; Hong CH
    J Cutan Med Surg; 2018; 22(1_suppl):10S-16S. PubMed ID: 30439297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What are the best outcome measurements for atopic eczema? A systematic review.
    Schmitt J; Langan S; Williams HC;
    J Allergy Clin Immunol; 2007 Dec; 120(6):1389-98. PubMed ID: 17910890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.